StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Aranesp (darbepoetin alfa by Quarter

Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide product sales ($M) ($M)

QuarterlyAnnual

Amgen Aranesp (darbepoetin alfa: $352M in Q2 2026, down 1.9% from a year earlier.

Latest, Q2 2026
352
Period ended Jun 30, 2026
Change on a year earlier
-1.9%
359 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026352-1.9%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026311-8.5%Form 10-Q (filed 2026-05-01) ↗
Q4 2025Dec 31, 2025333+8.1%Form 10-K (filed 2026-02-13) ↗
Q3 2025Sep 30, 2025357+5.9%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 2025359+3.2%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025340-2.6%Form 10-Q (filed 2026-05-01) ↗
Q4 2024Dec 31, 2024308-3.4%Form 10-K (filed 2026-02-13) ↗
Q3 2024Sep 30, 2024337+4.3%Form 10-Q (filed 2025-11-05) ↗
Q2 2024Jun 30, 2024348-4.7%Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024349-1.7%Form 10-Q (filed 2025-05-02) ↗
Q4 2023Dec 31, 2023319-8.3%Form 10-K (filed 2026-02-13) ↗
Q3 2023Sep 30, 2023323-9.8%Form 10-Q (filed 2024-10-31) ↗
Q2 2023Jun 30, 2023365+2.2%Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 2023355-0.8%Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 2022348-3.9%Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 2022358-9.6%Form 10-Q (filed 2023-10-31) ↗

Breakdown

What makes up aranesp (darbepoetin alfa

Cite this data

StockData. (2026). Amgen Aranesp (darbepoetin alfa ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-aranesp-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.